

## NHS ENGLAND SPECIALISED SERVICES CLINICAL PANEL REPORT

Date: April 2020

Intervention: Adalimumab

Indication: refractory chronic non-bacterial osteomyelitis/osteitis

ID: 1926

Gateway: 2 Round 1

Programme: Internal Medicine

CRG: Specialised Rheumatology

---

### Information provided to the Panel

Preliminary Policy Proposal

Clinical Priorities Advisory Group (CPAG) Summary Report

Policy Statement Proposition

Three evidence papers

---

### Key elements discussed

This policy statement proposition is a not for routine commissioning proposition for a rare auto-inflammatory condition. The incidence is estimated to be approximately 260 children per year in UK, mostly managed with non-steroidal anti-inflammatories and corticosteroids. There is currently no standard treatment pathway.

The evidence base presented to Panel was three papers - non comparative retrospective case series data. Clinical Panel discussed the limitations in all three studies presented to support the proposition. It was noted there was a small body of evidence and there was no ability to assess the effect of any one particular treatment due to concomitant and parallel treatment within the studies.

The Panel discussed that further research, or an evaluative study, would be useful as there was uncertainty in the current information.

---

### Recommendation

Clinical Panel recommends that this proposition progress as a not for routine commissioning policy proposition, as stated.

---

### Why the panel made these recommendations

The Panel considered that the proposition reflected the evidence base presented, which was weak.

---

## **Documentation amendments required**

Policy Proposition:

- Clinical Effectiveness Team to amend wording in policy proposition to reflect that any research or evaluation undertaken will need to have clear outcome measures.

---

Declarations of Interest of Panel Members: None.

Panel Chair: James Palmer, Medical Director Specialised Services.

## **Post-Panel Note:**

The above change has been incorporated into the policy statement.

EMMA